Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab Lorenz Kocheise; Jan Kempski; Yunhe Tang; Lorenz Balcar; Victoria Berger; Miriam Tomczak; Joao Gorgulho; Ramsha Masood; Franziska Giehren; Constantin Schmidt; Jan P. Sutter; Thorben W. Fruendt; Francesca Pagani; Sophie Wulf; Julian Kött; Saskia Domanig; Anastasios Giannou; Tanja Bedke; Jöran Lücke; Tao Zhang; Siwen Zhang; Andres Machicote; Ansgar W. Lohse; Marianna Alunni-Fabbroni; Jens Ricke; Najib Ben Khaled; Matthias Pinter; Bernhard Scheiner; Samuel Huber; Johann von Felden; Ignazio Piseddu; Kornelius Schulze;

Trends and health inequalities of hepatitis virus-associated liver cancer mortality during 1990¿2050 Yujiao Deng; Jingyue Tan; Jian Zu; Zixuan Xing; Zhanpeng Yang; Yue Zhang; Yajing Bo; Xu Gao; Enrui Xie; Yuan Wang; Meijuan Han; Fanpu Ji; Yang Yang;

MCM3 promotes hepatocellular carcinoma progression via Epithelial-mesenchymal Transition through AKT/Twist signaling pathway Wei-Guo Tang; Jin-Feng Feng; Xian Li; Qi-Man Sun; Jin-Wu Hu; Xiao-Lu Ma; Yan-Yan Nie; Yang Xu; Jian Sun; Qi-Meng Chang;